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The superfamily of the seven transmembrane G-protein-coupled receptors (7TM/GPCRs)
is the largest family of membrane-associated receptors. GPCRs are involved in the patho-
physiology of numerous human diseases, and they constitute an estimated 30–40% of
all drug targets. During the last two decades, GPCR oligomerization has been exten-
sively studied using methods like bioluminescence resonance energy transfer (BRET) and
today, receptor–receptor interactions within the GPCR superfamily is a well-established
phenomenon. Evidence of the impact of GPCR oligomerization on, e.g., ligand binding,
receptor expression, and signal transduction indicates the physiological and pharmacologi-
cal importance of these receptor interactions. In contrast to the larger and more thoroughly
studied GPCR subfamilies A and C, the B1 subfamily is small and comprises only 15 mem-
bers, including, e.g., the secretin receptor, the glucagon receptor, and the receptors for
parathyroid hormone (PTHR1 and PTHR2). The dysregulation of several family B1 recep-
tors is involved in diseases, such as diabetes, chronic inﬂammation, and osteoporosis
which underlines the pathophysiological importance of this GPCR subfamily. In spite of
this, investigation of family B1 receptor oligomerization and especially its pharmacological
importanceisstillatanearlystage.EventhoughGPCRoligomerizationisawell-established
phenomenon, there is a need for more investigations providing a direct link between these
interactions and receptor functionality in family B1 GPCRs. One example of the functional
effects of GPCR oligomerization is the facilitation of allosterism including cooperativity in
ligand binding to GPCRs. Here, we review the currently available data on family B1 GPCR
homo- and heteromerization, mainly based on BRET investigations. Furthermore, we cover
the functional inﬂuence of oligomerization on ligand binding as well as the link between
oligomerization and binding cooperativity.
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Abbreviations: αCGRP, α-calcitonin gene-related peptide (19–37); β-AR, β-
adrenergic receptor; BiFC, bimolecular ﬂuorescence complementation; BiLC,
bimolecular luminescence complementation; BRET, bioluminescence resonance
energy transfer; CALCR, calcitonin receptor; CaSR, Ca2+ sensing receptor;
CCKAR, cholecystokinin A receptor; CCR, chemokine receptor; CFP, cyan ﬂu-
orescent protein; co-IP, co-immunoprecipitation; CRH, corticotrophin-releasing
hormone; CRHR1 and CRHR2, corticotrophin-releasing hormone receptor-1 and
-2; CRLR, calcitonin receptor-like receptor; ECD, extracellular domain; ECL,
extracellular loop; FRET, ﬂuorescence resonance energy transfer; GABABR, γ-
aminobutyric acid receptor; GCGR, glucagon receptor; GFP, green ﬂuorescent
protein; GHRHR, growth hormone-releasing hormone receptor; GIP, glucose-
dependent insulinotropic polypeptide; GIPR, glucose-dependent insulinotropic
polypeptide receptor; GLP-1 and GLP-2, glucagon-like peptide-1 and -2; GLP-1R
and GLP-2R, glucagon-like peptide-1 and -2 receptors; GPCR, G-protein-coupled
receptor; GRH, growth hormone-releasing hormone; mGluR, metabotropic gluta-
mate receptor; PACAP, pituitary adenylate cyclase-activating peptide; PAC1, pitu-
itary adenylate cyclase-activating peptide receptor; PTH, parathyroid hormone;
PTHR1 and PTHR2, parathyroid hormone receptor-1 and -2; RAMP, receptor
INTRODUCTION
The seven transmembrane G-protein-coupled receptors (7TM/
GPCRs) comprise the largest family of membrane receptors.
Through coupling to intracellular heterotrimeric G-proteins, the
GPCRs mediate cellular responses to a diverse pallet of stimuli
includingphotons,odorants,ions,nucleotides,lipids,neurotrans-
mitters,proteases,and hormones (Bockaert and Pin,1999). Based
onstructuralandligandbindingcriteria,severalclassiﬁcationsys-
tems for GPCRs have been proposed, such as the A to F system
(Kolakowski, 1994) ,t h e1t o5s y s t e m( Bockaert and Pin, 1999),
and the GRAFS system (named after the ﬁrst letters of the ﬁve
activity-modifying protein; Rluc, Renilla luciferase; RXFP1 and RXFP2, relaxin
family peptide receptor-1 and -2; SECR, secretin receptor; TR-FRET, time-resolved
FRET; TSHR, thyrotrophin receptor;VIP, vasoactive intestinal peptide;VPAC1 and
VPAC2, vasoactive intestinal peptide receptor-1 and -2; V1bR, vasopressin V1b
receptor;YFP, yellow ﬂuorescent protein; 7TM, seven transmembrane.
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families Glutamate, Rhodopsin, Adhesion, Frizzled, and Secretin;
Fredriksson et al., 2003). In the Kolakowski system, the GPCRs
are classiﬁed into six families, A–F, of which only the families A,
B, and C are found in mammalian species (Kolakowski, 1994).
These families share little or no inter-family sequence homol-
ogy, even though the overall morphology of GPCRs is highly
conserved (Vohra et al., 2007; Kenakin and Miller, 2010). Fam-
ily A (rhodopsin-like receptors) is by far the largest family of
GPCRs,andmostreceptorsinthisfamilyarecharacterizedbyvery
short N- and C-termini. This family includes some of the most
extensively studied GPCRs: rhodopsin,the β-adrenergic receptors
(β-ARs), and the opioid receptors. Family C (metabotropic glu-
tamate receptors, mGluRs) includes, e.g., the mGluRs, the Ca2+
sensing receptor (CaSR), and the receptors for γ-aminobutyric
acid(GABABRs).ThisfamilyischaracterizedbyalongC-terminus
aswellasaverylongN-terminaldomainoftencontaininga“Venus
ﬂy-trap” structure responsible for ligand binding (Kristiansen,
2004; Kenakin and Miller, 2010). Family B is subdivided into the
subfamiliesB1(secretin-likereceptorfamily),B2[adhesionfamily,
or“longaminoterminus,familyB”(LNB-7TMproteins)],andB3
(Methuselah-like family) as proposed by Harmar (2001).A c c o r d -
ing to this classiﬁcation, the human B1 family of GPCRs includes
15 receptors, all responding to peptide hormones: the secretin
receptor(SECR),theglucagonreceptor(GCGR),theglucagon-like
peptide-1 and -2 receptors (GLP-1R and GLP-2R), the glucose-
dependentinsulinotropicpolypeptidereceptor(GIPR),therecep-
torsforparathyroidhormone(PTHR1andPTHR2),thereceptors
for vasoactive intestinal peptide (VPAC1 and VPAC2), the pitu-
itaryadenylatecyclase-activatingpeptidereceptor(PAC1),growth
hormone-releasinghormonereceptor(GHRHR),thereceptorsfor
corticotrophin-releasinghormone(CRHR1andCRHR2),thecal-
citonin receptor (CALCR), and the CALCR-like receptor (CRLR;
Harmar, 2001).
The natural ligands for family B1 GPCRs include secretin,
glucagon, GLP-1 and GLP-2, glucose-dependent insulinotropic
polypeptide (GIP), parathyroid hormone (PTH), vasoactive
intestinal peptide (VIP), pituitary adenylate cyclase-activating
peptide (PACAP), growth hormone-releasing hormone (GRH),
corticotrophin-releasing hormone (CRH), and calcitonin. These
peptide hormones and their receptors are currently of consid-
erable interest to the pharmaceutical industry because they are
involved in the pathophysiology of human diseases, such as, e.g.,
diabetes (glucagon, GLP-1, GIP; Knop et al., 2009; Bagger et al.,
2011; D’Alessio, 2011), osteoporosis (calcitonin, PTH; de Paula
and Rosen, 2010; Verhaar and Lems, 2010), inﬂammation, and
neurodegeneration (VIP, PACAP; Gonzalez-Rey et al., 2005). For
a full list of the involvement of family B1 GPCRs in diseases, see
Table 1.
STRUCTURE AND BINDING MECHANISM OF FAMILY B1 GPCRs
A common structural feature of the family B1 GPCRs is a rela-
tivelyshortC-terminusandalongN-terminaldomainof 100–200
residues (George et al., 2002). The characteristic structure of the
N-terminal region in family B1 includes two antiparallel β-sheets
(β1, β2, β3, and β4), an N-terminal α-helix, and six cysteines that
form three disulﬁde bridges. Furthermore, there is a conserved
disulﬁde bridge between cysteine residues in extracellular loop 1
(ECL1) and ECL2 (Ulrich et al., 1998; Authier and Desbuquois,
2008; Kenakin and Miller, 2010). Like their receptors, the peptide
ligands for the family B1 GPCRs are highly similar. They are all
relativelyshortpeptidesof 27–44aminoacidresiduesandtheyare
assumed to adopt an α-helical conformation during the contact
with their respective receptors (Grace et al.,2004).
TheN-terminalendofthereceptorextracellulardomain(ECD)
constitutestheprimaryreceptor–ligandinteractionsitethatdeter-
mines afﬁnity and speciﬁcity through binding of the C-terminal
portion of the ligand. This interaction constitutes the ﬁrst step
(step A) of ligand–receptor binding of family B1 in a model pro-
posed by Hoare and Usdin (2001;s e eFigure 1). Subsequently,
the ligand N-terminal portion interacts with the juxtamembrane
domain of the receptor (step B) resulting in receptor activation
(step C; Hoare and Usdin, 2001; Hoare, 2005; Tan et al., 2006).
Recently, crystal structures of ligand-bound ECDs have been
determined for several family B1 GPCRs, namely GIP (Parthier
etal.,2007),PTHR1(PioszakandXu,2008),GLP-1R(Rungeetal.,
2008), CRHR1 and -2 (Pioszak et al., 2008; Pal et al., 2010), and
T a b l e1|P o t ential therapeutical interests of targeting family B1 GPCRs and/or their natural ligands in human diseases.
Ligand Receptor(s) Disease(s) Reference
Glucagon GCGR Diabetes Ali and Drucker (2009), Bagger et al. (2011), D’Alessio (2011)
GIP GIPR Diabetes Knop et al. (2009)
GLP-1 GLP-1R Diabetes Deacon (2007), Knop et al. (2009)
GLP-2 GLP-2R Short bowel syndrome,
inﬂammatory bowel disease
Hornby and Moore (2011)
PTH PTHR1 and PTHR2 Osteoporosis de Paula and Rosen (2010), Verhaar and Lems (2010)
Calcitonin CALCR and CRLR Osteoporosis de Paula and Rosen, 2010
VIP VPAC1, VPAC2, and PAC1 Inﬂammation, neurodegeneration Gonzalez-Rey et al. (2005)
PACAP PAC1, VPAC1, and VPAC2 Inﬂammation, neurodegeneration Gonzalez-Rey et al. (2005)
CRH CRHR1 and CRHR2 Stress Stengel andTache (2010), Valdez (2009)
GRH GHRHR Dwarﬁsm Campbell et al. (1995)
Secretin SECR Gastrinoma Ding et al. (2002)
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FIGURE 1 |The two-step model of peptide ligand binding to family B1
GPCRs.The binding of one ligand to one family B1 GPCR occurs in two
steps. In step (A) the C-terminal portion of the ligand (blue) binds to the
N-terminal domain of the receptor with high afﬁnity and speciﬁcity. In step
(B), the N-terminal of the ligand (green) binds to the juxtamembrane
domain of the receptor.This activates the receptor and mediates
intracellular interaction with G-proteins [step (C)]. Modiﬁed from Hoare
(2005).
CRLR(terHaaretal.,2010).Thesestructuressupportthebinding
model proposed by Hoare and Usdin (2001) in which one ligand
binds to one receptor in a two-step process (Figure 1). However,
the interaction between the N-terminal portion of the ligand and
the juxtamembrane domain of the receptor may not be simpliﬁed
intoonesinglemodel.BasedonstudiesonSECR,VPAC1,CALCR,
and GLP-1R, an alternative model of receptor activation has been
proposed, involving the exposure of a hidden epitope in the N-
terminal domain of the receptor upon ligand binding that can act
as an endogenous agonist ligand (Dong et al.,2006,2008a,b).
GPCR OLIGOMERIZATION
G-protein-coupled receptors were originally thought to be
functional monomers, one receptor interacting with one het-
erotrimeric G-protein in a 1:1 stoichiometry. Today, however, the
phenomenon of GPCR homo- and/or heteromerization is widely
accepted, and several studies have revealed important functional
roles of GPCR oligomerization. In general, is it difﬁcult to dis-
tinguish between dimers and higher order oligomers of GPCRs
experimentally. Thus, we will refer to GPCR–GPCR interactions
as oligomers throughout this review unless the speciﬁc oligomeric
state has been determined.
InfamilyCof GPCRs,oligomerizationisafundamentaltheme;
forexample,thefunctionalGABABRisaheteromerofthetwopro-
tomers, GABAB1R and GABAB2R. The GABAB1R contains the
ligand binding site but is dependent on heteromerization with the
GABAB2Rprotomerforpropertransporttotheplasmamembrane
as well as for coupling to the G-protein signaling cascade (Galvez
et al.,2001;Comps-Agrar et al.,2011). The crystal structure of the
ECDof anotherfamilyCGPCR,themGluR,hasrevealedthatthis
receptor must be expressed on the cell surface as a homodimer in
ordertobefunctionalbecausetwomGluRprotomersincombina-
tion is needed to form the ligand binding cleft (Kunishima et al.,
2000).
Within family A of GPCRs there are also several examples of
functionality of oligomerization (Terrillon and Bouvier, 2004)a s
well as examples of the involvement of oligomerization in patho-
physiological conditions. The possibility that GPCR heteromer-
ization might play an important role in pharmacological diversity
wasﬁrstsuggestedbystudiesontheδ-andκ-opioidreceptors.Co-
expression of these receptors resulted in formation of heteromers
with a very low afﬁnity for either the δ-o rt h eκ-selective ligand
alone.However,whenthetwoligandswerecombined,highafﬁnity
was restored, suggesting the occurrence of positive cooperativity
(Jordan and Devi, 1999). This is very interesting in the context
of drug development because it might imply that selective com-
pounds can be designed that target speciﬁc heteromers without
affecting the individual protomers (George et al., 2002). Another
example comes from the study of platelets from preeclamptic
hypertensive women. This study revealed that an increase in the
relative number of heteromers between the AT1 receptor for the
vasopressor angiotensin II and the B2 receptor for the vasodepres-
sorbradykinincomparedtohomomersof therespectivereceptors
is involved in the pathophysiology of preeclampsia (AbdAllaetal.,
2001). It should be noted though, that others have been unable
to reproduce these notable ﬁndings in several cell lines (Hansen
et al.,2009; See et al.,2011).
In line with these examples for family A and C GPCRs,
oligomerization of family B1 GPCRs is likely to play an essen-
tial role in receptor function as well as in the pathophysiology
of the diseases listed in Table 1. Except for the SECR, which
has been extensively studied by Laurence Miller and his research
group as described later, not many studies have addressed the
functional issue of oligomerization in family B1 of GPCRs. How-
ever, given their importance in many severe diseases, including,
e.g., diabetes which alone currently affects 346 million people
worldwide (WHO, 2011), it is essential to clarify the interactions
between these receptors with the prospect of developing new and
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better treatments in the future. This review will focus on the cur-
rent status on homo- and heteromerization of family B1 GPCRs,
especially based on bioluminescence resonance energy transfer
(BRET)experimentsaswellasthepossiblefunctionallinkbetween
receptor oligomerization and binding cooperativity.
OLIGOMERIZATION IN THE FAMILY B1 OF GPCRs
METHODS USED TO STUDY OLIGOMERIZATION OF GPCRs
Different approaches have been taken to study GPCR oligomer-
ization over the last two decades. The ﬁrst GPCR oligomer
was indicated by the use of co-immunoprecipitation (Co-IP) by
Hebert et al. (1996). This method was used extensively in early
GPCR oligomerization studies. However, methods based on res-
onance energy transfer between two ﬂuorescently/luminescently
tagged receptors in living cells quickly gained traction. Today, the
method which is being used by far the most in GPCR oligomer-
ization studies is BRET. The principle of this method is relying
on the energy transfer between an enzyme energy donor, Renilla
luciferase (Rluc), and an energy acceptor usually in the form
of either green ﬂuorescent protein (GFP) or yellow ﬂuorescent
protein (YFP). In practice, an energy donor-tagged receptor is
co-expressedwithanenergyacceptor-taggedreceptorinacellsys-
tem. Upon receptor–receptor interaction, which brings the tags
into a proximity of <100Å, energy is transferred from the energy
donor to the energy acceptor upon activation of the Rluc enzyme.
This energy transfer results in a measurable acceptor emission
signal, the BRET signal, reﬂecting receptor–receptor interactions
(Pﬂeger and Eidne, 2006). The most convincing application of
thismethodisaBRETsaturationexperiment.Inthissetup,acon-
stant concentration of Rluc-tagged receptor is co-expressed with
an increasing concentration of GFP-tagged receptor. For a speciﬁc
receptor–receptor interaction, the BRET signal will increase with
increasing amounts of energy acceptor molecules and produce a
saturation curve. In contrast,a non-speciﬁc interaction will result
in a linear curve, the so-called “bystander BRET,” resulting from
randomcollisionsofthetaggedreceptors,therebyprovidinganeg-
ative control. Such a negative control is required for validation of
a speciﬁc interaction indicated in a BRET saturation experiment
(Hamdan et al.,2006).
Fluorescence resonance energy transfer (FRET) is a method
based on the same principle as BRET,however,FRET is relying on
theenergytransferbetweentwoﬂuorescentproteins,e.g.,YFPand
cyan ﬂuorescent protein (CFP). As in the case of BRET, FRET has
been used in numerous studies on GPCR oligomerization (Ayoub
and Pﬂeger,2010). Recently,the FRET-principle was improved by
includinglong-livedenergydonorssuchasterbiumandeuropium
in the so-called time-resolved FRET (TR-FRET). This technique
has the advantage of a lower background and thus a higher sig-
nal:noise ratio as compared to normal FRET (Albizu et al., 2010).
In addition, FRET is also being used to study GPCR oligomeriza-
tion by co-localization investigations using confocal microscopy,
a principle referred to as morphological FRET (Harikumar et al.,
2006).
Bimolecularﬂuorescencecomplementation(BiFC)andbimol-
ecular luminescence complementation (BiLC) are two other
recentlydevelopedﬂuorescence-basedtechniquesemployedinthe
study of GPCR oligomerization. These techniques apply splitting
eitheraﬂuorescentorluminescentproteinintwopartsandtagging
two receptors with a part each. Upon receptor–receptor interac-
tion, the two parts of the energy emitting protein will come in
close proximity and reassemble into a functional ﬂuorescent or
luminescent protein in a spontaneous reaction (Vidi et al.,2011).
All these different techniques have limitations and should in
general be combined in order to obtain convincing evidence of
GPCR oligomerization. It is, however, not the goal of this review
tocriticallycomparethebeneﬁtsandlimitationsof thesemethods
forwhichwerefertoreviewsonthesubject(MilliganandBouvier,
2005; Kaczor and Selent, 2011). In the following section, the use
of these different techniques for studying oligomerization within
the family B1 of GPCRs is reviewed.
OLIGOMERIZATION OF THE SECR, THE PROTOTYPICAL FAMILY B1 GPCR
Within the family B1 of GPCRs, the SECR is by far the most
thoroughly studied receptor. In 1991, SECR was the ﬁrst of the
family B1 receptors to be cloned (Ishihara et al., 1991). Due
to the similarity in sequences and structures of later character-
ized receptors of this family with the SECR, the B1 subfamily of
GPCRs has been named the “secretin-like receptors.” Extensive
studies on oligomerization properties of this prototypical family
B1 GPCR have been carried out by the laboratory of Laurence
Miller. SECR homomerization was indicated for the ﬁrst time
by morphological FRET in COS cells and further supported by
energy transfer between Rluc- and GFP-tagged SECRs in BRET
studies. Furthermore, this oligomerization was shown to be nec-
essary for the functionality of the SECR since co-expression of a
missplicedSECRwithwild-type(WT)SECRhadadominantneg-
ative effect on receptor function (Ding et al., 2002). Importantly,
secretinregulatesgrowth-inhibitoryeffectsthroughtheSECRand
the misspliced SECR has been found in gastrinoma. Thus het-
eromerization between the two, resulting in dominant negative
activity of the misspliced SECR on the WT SECR, was specu-
lated to facilitate tumor growth (Ding et al., 2002). This work
on the SECR provided the ﬁrst example of the functional and
physiological relevance of oligomerization within the GPCR B1
family.
Using BRET, one cannot readily distinguish between dimers
and higher order oligomers. Thus, in order to investigate the
oligomeric state of the SECR, Millers group in 2008 used a
combination of BiFC and BRET. The results of this study
showed energy transfer between two but not three of the ﬂuo-
rescently/luminescently tagged SECRs, indicating that the SECR
forms dimers but not higher order oligomers (Harikumar et al.,
2008a).
The interaction site between two SECR protomers within a
dimer has also been investigated by Miller’s group. By compet-
ing SECR dimer interactions measured by BRET with the co-
expression of isolated SECR transmembrane (TM) sections, the
interaction site of a SECR dimer was mapped to TM4 (Lisenbee
and Miller, 2006). Further, by the use of mutational studies, the
exact interaction site was localized to two speciﬁc residues in the
lipid-exposedfaceof TM4,namelyGly243andIle247(Harikumar
et al.,2007). Subsequent mutations of these sites enabled compar-
ative studies on ligand binding and signaling on receptor dimers
versus monomers. These studies showed that SECR monomers
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havesimilarligandbindingpropertiesasSECRdimers.Incontrast,
thepotencyforcAMPproductionwasdecreasedforthemonomer,
indicatingthatthedimericstateoftheSECRisrequiredforcorrect
G-protein coupling (Harikumar et al., 2007). Thus, dimerization
is important for optimal signaling of the SECR, thereby adding
evidence to the physiological and pharmacological importance of
family B1 GPCR oligomerization.
Finally, an extensive study using BRET to detect heteromer-
ization between the SECR and other members of the family B1
GPCRs was published in 2008 (Harikumar et al.,2008b). Interest-
ingly, this study revealed a basic constitutive interaction between
SECRandalmostallothertestedfamilyB1GPCRs,includingGLP-
1R, GLP-2R, GHRHR,VPAC1 and -2, PTHR1 and -2, and CRLR.
Thisindicatesapossiblebroadcommunicationbetweenreceptors
ofthefamilyB1GPCRs.Theonlyreceptorofthisstudythatturned
out not to interact with the SECR was the CALCR. The absence
of heteromerization between these receptors was suggested to be
causedbythepresenceoftwodifferentresiduesintheCALCRTM4
(shown to be the dimer interaction site for SECR) not present in
any other of the tested family B1 GPCRs (Harikumaretal.,2008b;
for further details, see below).
OLIGOMERIZATION OF THE GLUCAGON RECEPTOR FAMILY OF B1 GPCRs
The GCGR family branch of the family B1 GPCRs consists of
the structurally related GLP-1R, GCGR, and GIPR, which are all
involved in the intricate control of blood-glucose levels (Holst
et al.,2011),as well as the GLP-2R.
Homo- and heteromerization studies within this subfamily
have been carried out by Schelshorn et al. (2011) using the BRET
technique.Themostinterestingﬁndingof thisstudywastheasso-
ciation of the GLP-1R and the GIPR in a heteromer complex
induced by stimulation with GLP-1. This is the ﬁrst indication
of ligand-induced oligomerization in the family B1 GPCRs. The
effect of GLP-1 on the GLP-1R/GIPR heteromer assembly seemed
to be reversed by GIP stimulation,which led to dissociation of the
heteromer complex. This ﬁnding was validated by BRET satura-
tionexperiments,negativecontrols,aswellasBRETkineticexperi-
mentswheretheGLP-1-inducedheteromerizationwasfoundtobe
very fast occurring within 30s after ligand addition. Furthermore,
a functional role of the GLP-1R/GIPR heteromer was indicated.
Upon co-expression of the GLP-1R with the GIPR, GLP-1R sig-
naling was altered and the β-arrestin recruitment was reduced
(Schelshornetal.,2011).Theseﬁndingsindicateafunctionalinter-
action between the receptor targets of the two important incretin
hormones that together regulate post-prandial blood-glucose lev-
els by potentiating insulin secretion from the pancreatic β-cells
(Holst et al.,2009).
In addition to the GLP-1R/GIPR heteromer, Schelshorn et al.
(2011) also investigated homo- and heteromerization of the other
membersof theGCGRfamilyB1GPCRs.Homomerizationof the
GLP-1RaswellastheGIPRwasclaimedtobefoundinBRETsatu-
ration experiments. Furthermore,stimulation of these homomers
with GLP-1 and GIP,respectively,was found to slightly reduce the
BRETsignalindicatingeitherareducedafﬁnityorconformational
changes in the receptor homomers upon ligand binding. How-
ever, these results were not compared with a negative control nor
were there any statistical evaluation supporting this theory in the
publication. We have performed similar BRET saturation exper-
iments on GLP-1R homomerization showing a saturation curve
but no effect of GLP-1 stimulation (see Figure 2A; Roed, 2011).
Severalattemptstovalidatethisspeciﬁcreceptor–receptorinterac-
tion by negative controls were,however,unsuccessful. Thus,it still
remainstobeﬁrmlyestablishedwhetherGLP-1Rhomomerization
occurs.
Schelshorn et al. (2011) also indicated homomerization of the
GCGR as well as the GLP-2R by BRET studies. However, these
FIGURE 2 | Bioluminescence resonance energy transfer saturation
studies on homo- and heteromerization of GLP-1R and GCGR.These
BRET studies were performed as BRET
2 saturation assays, which uses a
spectrally improved form of the luciferase enzyme substrate (coelenterazine),
DeepBlueC, as well as a modiﬁed form of the energy acceptor, GFP
2 (Pﬂeger
and Eidne, 2006). In addition, a mutationally improved energy donor, Rluc8,
with increased stability and quantum yield was used (De et al., 2007). HEK293
cells were transiently co-transfected with a constant amount of either
GCGR-Rluc8 or GLP-1R-Rluc8 and an increasing amount of either GCGR-GFP
2
or GLP-1R-GFP
2 and incubated for 48h at 37˚C and 5% CO2. Subsequently,
the cells were harvested, diluted to a concentration of 1×10
6 cells/ml, and
stimulated with either 105nM GLP-1, 83.5nM glucagon, or buffer (negative
control) for 5min at room temperature.The BRET
2 signal was measured upon
addition of the Rluc8 substrate, DeepBlueC in a Mithras plate reader. All data
are plotted as the BRET
2 level as a function of the GFP
2/Rluc8 ratio and ﬁtted
to a one-site speciﬁc binding model in GraphPad Prism. A saturating curve
indicates a speciﬁc interaction between the Rluc- and GFP
2-tagged receptor.
The data represent mean±SD of three independent experiments carried out
in quadruplicates. (A) GLP-1R-Rluc8/GLP-1R-GFP
2 homomerization in the
presence (blue) or the absence (gray) of 105nM GLP-1 (Roed, 2011). (B)
GCGR-Rluc8/GCGR-GFP
2 homomerization in the presence (green) or the
absence (gray) of 83.5nM glucagon (Orgaard, 2011). (C)
GCGR-Rluc8/GLP-1R-GFP
2 heteromerization in the presence of either 105nM
GLP-1 (blue), 83.5nM glucagon (green), or buffer (gray) (Orgaard, 2011).
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results were not validated by BRET saturation experiments nor
by negative controls. Figure 2B (Orgaard, 2011) shows our own
results:aBRETsaturationexperimentwiththeGCGRinthepres-
ence or the absence of glucagon. A saturation curve was observed
indicating homomerization of the GCGR with no effect of lig-
and addition. However, again, attempts to validate these data by
negative controls were unsuccessful.
Finally, heteromerization for all possible interaction pairs of
the structurally related receptors of the GCGR family was inves-
tigated by Schelshorn et al. (2011), by BRET studies testing
both possible combinations of Rluc/YFP- or YFP/Rluc-tagged
receptor pairs (e.g., both GLP-1R-Rluc/GCGR-YFP and GLP-1R-
YFP/GCGR-Rluc).AsmallbutsigniﬁcantreducingeffectofGLP-1
on GLP-1R/GCGR heteromerization was observed as well as a
small and signiﬁcant reducing effect of both glucagon and GLP-2
onGCGR/GLP-2Rheteromerization.Theseresultswere,however,
not reproducible upon shifting from an Rluc/YFP-tagged to an
YFP/Rluc-tagged receptor pair. Such differences in the BRET sig-
nal upon a shift in the tagging of the receptor pair can result from
(1) differences in receptor expression levels inﬂuencing the ratio
of formed homomers:heteromers or (2) changes in the relative
orientation between the two tags known to affect the BRET sig-
nal (Ayoub and Pﬂeger, 2010). Further studies supporting either
of the two possibilities were not carried out and thus no con-
clusion on the effect of ligand stimulation of GLP-1R/GCGR as
well as GCGR/GLP-2R heteromers can be drawn from this study.
We have performed BRET saturation experiments on cells co-
expressing GLP-1R and GCGR resulting in saturation curves (see
Figure2C;Orgaard,2011).Here,nochangeinthesaturationcurve
was observed upon addition of either GLP-1 or glucagon.
Thus, within the GCGR subfamily an example of the physio-
logical importance of family B1 GPCR oligomerization has been
found for the GLP-1R/GIPR heteromer. BRET experiments indi-
cating homo- and heteromerization of the other members of the
GCGRsubfamilyhavealsobeenattempted.However,noﬁrmcon-
clusions can be drawn without further investigations including
proper negative controls.
OLIGOMERIZATION OF THE “NON-PROTOTYPICAL” AND
“NON-GLUCAGON RECEPTOR FAMILY” B1 GPCRs
In addition to the prototypical SECR and the glucagon subfam-
ily receptors, oligomerization among almost all other family B1
GPCRs has now been reported.
An interesting case is the PTHR1. Crystal structures of the iso-
lated ECD of this receptor in its ligand-bound state showed a
monomeric receptor with ligand binding in a 1:1 stoichiometry
(Pioszak and Xu, 2008; Pioszak et al., 2009). However, in 2010
the crystal structure of the unbound PTHR1 ECD was published,
surprisingly showing a dimerization between two ECDs (Pioszak
et al., 2010). Interestingly, this dimerization was mediated by the
receptor ECD C-termini taking up α-helical structures, similar to
the helix of the ligand,PTH. The receptor C-termini bound to the
binding site of the opposing PTHR1 protomer in the absence of
ligand.Thiscross-linkingispossibleduetothesequencesimilarity
between the receptor ECD C-terminal and PTH. The oligomer-
ization of the full-length PTHR1 in the absence of PTH was
conﬁrmed by BRET saturation studies as well as morphological
FRET in living cells. As predicted from the presence of recep-
tor ECD dimerization only in the ligand unbound state found
by crystallography, PTH stimulation of the receptors in BRET
studies resulted in dissociation of PTHR1 oligomers. In agree-
ment with receptor monomerization upon ligand binding and
activation, the monomeric PTHR1 was found to be sufﬁcient for
coupling and activation of G-proteins. In addition, it was shown
thatPTHR1oligomerizationdidnotinﬂuenceeitherreceptorsur-
face expression or ligand binding and signaling (Pioszak et al.,
2010). Hence, PTHR1 provides an interesting example of family
B1 GPCR oligomerization where constitutive presumably dimeric
receptors on the cell surface are disrupted upon ligand binding,
and, therefore, likely does not inﬂuence the functionality of the
receptor. Interestingly,stimulation with PTH has also been shown
to disrupt interactions between the SECR and both the PTHR1
and the PTHR2 (Harikumar et al., 2008b) conﬁrming the homo-
mer disruption effects of PTH and the full functionality of a
monomeric PTHR. The effects of ligand binding to GPCRs on
GPCRoligomerizationwithinfamilyB1issummarizedinTable 2.
Another example in family B1 GPCRs where oligomeriza-
tion does not inﬂuence receptor function is the VPAC1 and
VPAC2 receptors. These receptors were shown to interact in both
homomers and heteromers by BRET studies in 2006 (Hariku-
mar et al., 2006). Later that same year, these interactions were
further supported by Co-IP studies (Langer et al., 2006). Simi-
lar to the case of PTH binding to the PTHR1, binding of VIP to
the VPACs disrupted receptor–receptor interactions (Harikumar
et al.,2006). ThisVIP-inducedVPAC oligomer disruption has not
yetbeenfollowedupbystructuralinvestigationsasforthePTHR1.
Yet, the VPAC oligomerization was shown not to affect either lig-
andbinding,receptorsignaling,orinternalization.Thisindicatesa
monomericfunctionalVPACdespitethepresenceofnativeconsti-
tutivereceptoroligomerssimilartothecaseof thePTHR1(Langer
et al.,2006).
The PTHR1 and VPAC receptors provide examples of the
familyB1GPCRswhereoligomerizationdoesnotinﬂuencerecep-
tor functionality. An example of the opposite situation where
oligomerization does indeed inﬂuence the function of the GPCR
can be found in the binding of GHRH to the GHRHR. Oligomer-
ization between this receptor and a splice variant has been con-
ﬁrmed by Co-IP and shown to decrease ligand binding. The
reduced ligand binding was not caused by a decreased receptor
surfaceexpressionindicatingthatoligomerizationhasadominant
negative signaling effect on the function of GHRHR (McElvaine
and Mayo, 2006). Another example of dominant negative effects
of GPCR family B1 oligomerization is found in the CALCR. CAL-
CRs form constitutive homomers which are not inﬂuenced by
ligand binding as investigated by Co-IP and FRET experiments
(Seck et al., 2003). As in the case of the SECR, homomeriza-
tion of the CALCR was found to be important for the expression
and functionality of the receptor, since heteromerization with a
CALCR splice variant lead to reduced signaling. Heteromeriza-
tion with the splice variant receptor thus had a dominant negative
effect on the function of the WT CALCR. These studies were car-
ried out using the rabbit CALCR (rCALCR; Seck et al., 2003).
Interestingly, in a later study on the human CALCR (hCALCR),
BRET experiments did not show any signals signiﬁcantly different
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Table 2 | Oligomerization of the family B1 GPCRs and the effect of ligand binding.
Oligomer Ligand Ligand effect on oligomerization Reference
HOMOMERS
SECR/SECR Secretin None Ding et al. (2002), Harikumar et al. (2006)
GLP-1R/GLP-1R GLP-1 None Orgaard (2011), Roed (2011), Schelshorn et al. (2011)
GIPR/GIPR GIP None Schelshorn et al. (2011)
GCGR/GCGR Glucagon None Orgaard (2011), Roed (2011), Schelshorn et al. (2011)
GLP-2R/GLP-2R GLP-2 None Schelshorn et al. (2011)
PTHR1/PTHR1 PTH Reducing Pioszak et al. (2010)
VPAC1/VPAC1 VIP Reducing Harikumar et al. (2006)
VPAC2/VPAC2 VIP Reducing Harikumar et al. (2006)
GHRHR/GHRHR GRH N/A McElvaine and Mayo (2006)
rCALCR/rCALCR Calcitonin None Seck et al. (2003)
CRLR/CRLR Calcitonin None Heroux et al. (2007)
CRHR1/CRHR1 CRH None Kraetke et al. (2005),Young et al. (2007)
PAC1/PAC1 PACAP N/A Maurel et al. (2008)
HETEROMERS
SECR/GLP-1R Secretin None Harikumar et al. (2008b)
GLP-1 None
SECR/GLP-2R Secretin None Harikumar et al. (2008b)
GLP-2 None
SECR/PTHR1 Secretin Reducing Harikumar et al. (2008b)
PTH Reducing
SECR/PTHR2 Secretin Reducing Harikumar et al. (2008b)
PTH Reducing
SECR/VPAC1 Secretin None Harikumar et al. (2006)
VIP None
SECR/VPAC2 Secretin None Harikumar et al. (2006)
VIP None
SECR/GHRHR Secretin None Harikumar et al. (2008b)
GRH None
SECR/CRLR Secretin None Harikumar et al. (2008b)
αCGRP None
GLP-1R/GIPR GLP-1 Inducing Schelshorn et al. (2011)
GIP Reducing
GLP-1R/GCGR GLP-1 None Orgaard (2011), Roed (2011), Schelshorn et al. (2011)
Glucagon None
GLP-1R/GLP-2R GLP-1 None Orgaard (2011), Roed (2011), Schelshorn et al. (2011)
GLP-2 None
GCGR/GIPR Glucagon None Schelshorn et al. (2011)
GIP None
GCGR/GLP-2R Glucagon None Schelshorn et al. (2011)
GLP-2 None
GIPR/GLP-2R GIP None Schelshorn et al. (2011)
GLP-2 None
VPAC1/VPAC2 VIP Reducing Harikumar et al. (2006)
αCGRP , α-calcitonin gene-related peptide (19–37); N/A, data not available.
from baseline, indicating that the hCALCR does not homomer-
ize (Harikumar et al., 2010). From alignment of the sequences
of the rCALCR and the hCALCR a residue (aa 236) in the TM4
of the hCALCR (Arg) differing from rCALCR (His) as well as
from all other human family B1 GPCRs was localized. Since TM4
has been assigned the interaction interface of SECR dimers, as
previously described (Harikumar et al., 2007), it was speculated
whether the lack of hCALCR homomerization was caused by
this change in the hCALCR TM4 sequence. In support of this,
mutation of the hCALCR TM4 residue to the rCALCR residue
(A263H) resulted in a signiﬁcant increased BRET signal indicat-
inghCALCRhomomerization.FurtherconﬁrmingtheTM4asthe
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CALCR homomerization interface, the co-expression of the iso-
lated hCALCR TM4 with rCALCR reduced the homomerization
of rCALCR in a BRET competition experiment (Harikumar et al.,
2010).TheCALCRthusmakesupaninterestingexampleoffamily
B1 GPCR oligomerization showing species-speciﬁc differences in
the ability to engage in receptor–receptor interactions.
Finally,theCRHR1hasbeenshowntoformconstitutivehomo-
mers which are unaffected by ligand binding (Kraetke et al.,2005;
Youngetal.,2007)aswellashomomersof thePAC1andtheCRLR
receptors have been indicated (Kraetke et al., 2005; Maurel et al.,
2008). To our knowledge, the only family B1 GPCR that has not
yet been investigated for oligomerization is the CRHR2.
INTER-FAMILY OLIGOMERIZATION OF GPCRs
As mentioned, GPCR families A, B, and C share a highly con-
served general morphology, but little or no inter-family sequence
homology. Hence, the search for a common sequence responsible
for GPCR oligomerization has so far been fruitless (Vohra et al.,
2007).Evenamongreceptorsfromthesamefamily(familyA),dif-
ferentcombinationsof allsevenTMdomainshavebeenidentiﬁed
as contact points between protomers depending on the recep-
tor examined (GPCR-OKB, 2012). This implies that the speciﬁc
residues on TM4 responsible for homodimerization of the SECR
(Harikumaretal.,2007)andhomomerizationofCALCR(Hariku-
mar et al.,2010) may not necessarily be the same residues that are
involved in homomerization between other family B1 members,
orinheteromerizationbetweentheSECRortheCALCRandother
family B1 GPCRs. Interestingly,as well as intra-family heteromer-
izationhasnowbeendemonstratedtobewidespread,inter-family
heteromerization has also been reported to occur.
There are a couple of reports of GPCR inter-family heteromer-
izationinvolvingfamilyB1receptors.Functionalheteromers,mea-
sured by their ability to induce cAMP production upon ligand
stimulation, have been reported between two family A members,
β2-AR and opsin, and the family B1 member GIPR (Vrecl et al.,
2006). Also, the family A vasopressin V1b receptor (V1bR) has
been shown to form constitutive heteromers with the family B1
CRHR1. However, the study did not reveal any obvious effects of
heteromerization on the pharmacological properties of V1bR and
CRHR1 (Young et al., 2007). In line with these reports, BRET
results have suggested that the family B1 GCGR is capable of
forming heteromers with the family A cholecystokinin A receptor
(CCKAR; Orgaard,2011).
In addition to the ability of family B1 GPCRs to interact with
othertypesofGPCRs,thesereceptorsmayalsorelyoninteractions
with other types of membrane proteins for proper function or in
order to diversify their physiological functions. It has been shown,
that the CALCR and the CRLR as well as the VPAC1 can interact
with some of the receptor activity-modifying proteins, RAMP1,
-2, and/or -3 thereby assembling a variety of receptor types with
different speciﬁcities for endogenous peptide ligands or altered
signaltransductionproperties(Christopoulosetal.,2003;Barwell
et al.,2011).
Taken together, the accumulating evidence of various types
of GPCR heteromers suggests that all GPCRs share a common
propensity to heteromerize, and that tissue-speciﬁc expression
patterns are probably responsible for creating a much greater
diversity of GPCR signaling than would have been expected from
a 1:1 GPCR:G-protein stoichiometry.
LINK BETWEEN OLIGOMERIZATION AND BINDING
COOPERATIVITY IN GPCRs
Asdescribed,GPCRoligomerizationcanhavedifferentfunctional
effects on,e.g.,receptor expression,signaling,and ligand binding.
One example of the functional effects of GPCR oligomerization is
thefacilitationof allosterisminligandbindingtoGPCRs.Accord-
ing to the current knowledge, most GPCRs bind their ligands
in a 1:1 ligand:receptor stoichiometry (Hoare and Usdin, 2001;
Kristiansen, 2004). One example of an allosteric interaction is
cooperativity,inwhichbindingof aligandtoonereceptorbinding
site changes the binding afﬁnity to another receptor binding site
andviceversa.Thisisknownasreciprocityandisoneof theessen-
tial features of allosteric interactions (Gregory et al., 2010). For a
detailed review on allostery at GPCR oligomers, Smith and Mil-
ligan (2010). The presence of cooperativity in binding of ligands
to GPCRs does not correspond to the hypothesis of a 1:1 bind-
ing stoichiometry (see Figure 1), since more than one binding
site is required for allosteric interactions to occur. Thus, cooper-
ativity in GPCR ligand binding constitutes a strong indication of
oligomerization (although this assumption has been challenged
(Chabre et al., 2009). Cooperativity can be either positive or neg-
ative depending on whether the binding of a second ligand to a
second receptor binding site increases or reduces the afﬁnity of a
pre-bound ligand to the ﬁrst receptor binding site.
OvertheyearsofGPCRinvestigations,severalexamplesofneg-
ativecooperativityinthebindingof ligandstothesereceptorshave
beenreported.Recently,thepresenceof thisbindingphenomenon
has been directly linked to GPCR oligomerization.
The classical approach for detection of negative cooperativity
istomonitorthedissociationof radioactivelylabeledligandinthe
absence or presence of unlabeled ligand using an “inﬁnite dilu-
tion” procedure, as ﬁrst proposed for the insulin receptor by De
Meyts et al. (1973). In this procedure, a small fraction of the sur-
faceexpressedreceptorsarepre-occupiedby 125I-labeledligandin
an initial association step followed by dissociation in an inﬁnite
dilutionofeitherbufferaloneorbufferwithanexcessofunlabeled
ligand. In practice, the “inﬁnite dilution” should be sufﬁcient to
prevent rebinding of the tracer (De Meyts et al.,1973). If the pres-
enceofanexcessofunlabeledligandacceleratesthedissociationof
pre-bound 125I-labeled ligand, it means that binding of the unla-
beledligandtoasecondbindingsitedecreasestheligandafﬁnityat
theﬁrstbindingsite.Thisisthehallmarkof negativecooperativity
(Koshland, 1996).
LINK BETWEEN OLIGOMERIZATION AND BINDING COOPERATIVITY OF
GPCRs
In the mid 1970s, many years before the β2-AR was recognized
as a GPCR, negative cooperativity was observed in the binding
between this receptor and its ligand (Limbird et al.,1975;Limbird
and Lefkowitz, 1976). When the β2-AR was later classiﬁed as a
GPCR, a receptor type believed at that time to be a monomeric
entity,theearlierﬁndingofnegativecooperativitybecameamatter
of dispute(forreview,seeDeMeyts,1976,2008).Manyyearslater,
the β2-AR was established to be a functional homomer (Hebert
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etal.,1996;Angersetal.,2000),anobservationthatoffersanexpla-
nation for the observed negative binding cooperativity. However,
no direct correlation between oligomerization and negative coop-
erativity has yet been established for the β2-AR. It has even been
suggestedthatthemonomericβ2-ARcanfullycoupletoG-protein
and exhibit cooperativity in binding (Whorton et al., 2007).
A direct correlation between negative cooperativity and recep-
tor oligomerization was reported in 2005 for the family A GPCR
thyrotrophin receptor (TSHR; Urizar et al., 2005). In this study,
a combination of BRET assays and radioligand binding assays
revealed that the TSHR homomerizes and displays negative coop-
erativity in the binding of its ligand (as shown earlier, De Meyts,
1976). In line with the accumulating evidence that most,if not all,
family A GPCRs may oligomerize (Terrillon and Bouvier, 2004),
this led the authors to speculate that cooperativity is a general
phenomenon in family A GPCRs (Urizar et al., 2005). Indeed,
several recent investigations have yielded results supporting this
concept. In 2005 and 2006, negative cooperativity was found in
the binding of chemokines to chemokine receptor (CCR) homo-
andheteromers(El-Asmaretal.,2005;Springaeletal.,2006).Fur-
thermore, in 2008, a possible link between negative cooperativity
and GPCR oligomerization was indicated for the relaxin family
peptidereceptor1(RXFP1)andRXFP2(Svendsenetal.,2008a,b).
Existence of positive cooperativity has also been reported in the
bindingofligandstoGPCRs.Anexampleofthisisarecentstudyby
Gomes et al. (2011) suggesting that heteromers of μ and δ opioid
receptors display strong positive cooperativity in ligand binding.
LINK BETWEEN OLIGOMERIZATION AND BINDING COOPERATIVITY IN
FAMILY B1 GPCRs
In family B1 GPCRs, the extensive studies of the SECR by Miller
and his group have also revealed a role for negative cooperativity
in binding of secretin to the SECR. After localizing the speciﬁc
residues responsible for SECR homodimer formation to TM4
(Harikumar et al., 2007), these residues were mutated producing
a monomeric SECR. The dimeric WT SECR was then shown to
display negative cooperativity in the binding of secretin, whereas
the mutated monomeric SECR had lost this ability (Gao et al.,
2009). These results provide the ultimate link between negative
cooperativity and GPCR oligomerization. Another example of
a link between negative cooperativity and receptor oligomeriza-
tion of the family B1 GPCRs is indicated for the GLP-1R and
GCGRs. As described previously and indicated by BRET satura-
tion studies in Figure 2, these receptors might form constitutive
oligomers. In radioligand binding assays, an accelerated dissoci-
ation of pre-bound 125I-labeled ligand in the presence of excess
of unlabeled ligand suggested the existence of negative cooper-
ativity in the binding between GLP-1 and the GLP-1R as well
as in the binding between glucagon and the GCGR (Figure 3;
Orgaard,2011;Roed,2011).Negativecooperativityinligandbind-
ing to the GLP-1R and GCGR suggests the presence of at least
two binding sites for each of the receptors. Since only one lig-
and bind per family B1 GPCR, as suggested by Hoare and Usdin,
2001; Figure 1), the presence of negative cooperativity supports
the otherwise invalidated BRET saturation studies (Figures 2A,B;
Orgaard, 2011; Roed, 2011) indicating homomerization of GLP-
1R and GCGR. Thus, negative cooperativity in ligand binding to
GPCRs can provide a functional support for GPCR oligomeriza-
tion. Since the link between negative cooperativity and receptor
oligomerization has been shown for the prototypical family B1
receptor, the SECR, as well as indicated for the GLP-1R and
the GCGR, it can be speculated that this is a general phenom-
enon within family B1. However, this will have to be further
investigated.
FIGURE 3 | Dissociation experiment investigating negative
cooperativity in the binding of GLP-1 and glucagon to the GLP-1R and
the GCGR, respectively.These dissociation assays were carried out as
described by De Meyts et al. (1973) for the insulin receptor. In this
procedure, a small fraction of the surface expressed receptors are
pre-occupied by
125I-labeled ligand in an initial association step followed by
dissociation in an “inﬁnite dilution” of either buffer of buffer containing an
excess of unlabeled ligand. Accelerated dissociation of
125I-labeled ligand in
the presence of unlabeled ligand indicates the presence of negative
binding cooperativity.The data are plotted as the logarithm of
bound/bound0 as a function of time in minutes and ﬁtted to a two-site
exponential decay model in GraphPad Prism. All data represent mean±SD
of three independent experiments carried out in duplicates. (A)
Dissociation of GLP-1 from the GLP-1R. A concentration of 5×10
6 cells/ml
BHK cells stably transfected with the GLP-1R were incubated with
150,000cpm
125I-labeled GLP-1 for 3h at 15˚C. Subsequently, the unbound
125I-GLP-1 was aspired and the cells were diluted 1:40 in either HEPES
binding buffer (gray) or HEPES binding buffer with 167nM unlabeled GLP-1
(blue) and incubated at 25˚C allowing ligand dissociation for up to 1440min
(24h) (Roed, 2011). (B) Dissociation of glucagon from the GCGR. A
concentration of 5×10
6 cells/ml BHK cells stably transfected with the
GCGR were incubated with 150,000cpm
125I-labeled glucagon for 1h at
15˚C. Subsequently, the unbound
125I-glucagon was removed and the cells
were diluted 1:40 in either HEPES binding buffer (gray) or HEPES binding
buffer with 167nM unlabeled glucagon (green) and incubated at 25˚C
allowing ligand dissociation for up to 180min (3h) (Orgaard, 2011).
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SUMMARY AND CONCLUSION
Here, we have reviewed the currently available data on oligomer-
ization of the family B1 GPCRs. Studies on this family have
revealed indications on homomerization of almost all members
belonging to this subfamily of GPCRs. Even though not all of
these studies have been as extensive as the studies on the proto-
typical family B1 GPCR, the SECR, the accumulating data and
evidence points in the direction of homomerization as a gen-
eral phenomenon for family B1 GPCRs. This is in line with the
many publications on oligomerization of other classes of GPCRs
(Milligan,2001; George et al.,2002).
In addition to the increasing evidence of homomerization
within family B1 GPCRs, several studies have also indicated het-
eromerization between different receptors of this family. The
extensivestudyontheSECRindicatingheteromerizationbetween
this prototypic receptor and almost all other family B1 GPCRs is
a good example (Harikumar et al., 2008b). However, the study by
Harikumar et al. also revealed a single family B1 GPCR that did
not interact with the SECR, namely the CALCR with the lack of
interaction likely caused by differences in key residues in TM4.
Thus, there seems to be exceptions from the rule of a general het-
eromeric communication network in the family B1 GPCRs. Also,
it is important to remember, that the physiological importance of
such an intra- and possibly also inter-family cross-talk network
for B1 GPCRs is dependent on the co-expression of the involved
receptors in native tissue.
Interestingly, despite the many studies on family B1 GPCR
oligomerization, no general effect of ligand binding to family B1
oligomers has been found. Indeed, most of these receptors seem
to form constitutive oligomers with no effect of ligand binding
(Table 2).Yet,examplesonboththeinduction(GLP-1RandGIPR;
Schelshorn et al., 2011) and disruption of receptor oligomeriza-
tion (PTHR1; Pioszak et al.,2010 andVPAC1/2; Harikumar et al.,
2006) in response to ligand binding have been indicated. This is
interesting, since a common effect of ligand binding on GPCR
oligomerization would be expected from the common model
for the binding mechanism of ligands to family B1 GPCRs, as
suggested by Hoare and Usdin (2001;s e eFigure 1).
Even though the many evidences on GPCR oligomerization
cannot be neglected, the functionality of these receptor–receptor
interactions is controversial and extensively debated. In family
B1 GPCRs, only a few examples on GPCR oligomer function-
ality are available, e.g., the importance of SECR homodimer-
ization for receptor expression and full intracellular G-protein
coupling (Harikumar et al., 2007). However, family B1 GPCRs
also provide examples on receptors which are fully functional
in their monomeric form, such as the PTHR1 (Pioszak et al.,
2010).
An important functional aspect of GPCR oligomerization
is the possibility of cooperativity in ligand binding to these
receptors. A strong link between negative cooperativity and
GPCR oligomerization has been found for a family A GPCR,
the THSR, as described previously (Urizar et al., 2005). Yet,
to our knowledge, the only published data on such a link for
the family B1 GPCRs is the SECR (Gao et al., 2009). In addi-
tion, we have here presented data indicating a similar link
between oligomerization, as indicated by BRET experiments,
and negative cooperativity, as indicated by dissociation bind-
ing experiments, for the GLP-1R and GCGR (Figures 2A,B and
3; Orgaard, 2011; Roed, 2011). However, to obtain a strong
direct link between these two phenomena, further studies like
mutational studies and functional complementation studies are
required.
In conclusion, homomerization and to some extent also het-
eromerization of family B1 GPCRs seem to be a general phenom-
enon. However, only a few studies on the functionality of these
receptor–receptor interactions are currently available. The family
B1 GPCRs are very important receptors since they are almost all
involved in diseases affecting millions of people worldwide, such
as diabetes,osteoporosis and chronic inﬂammation. Thus,further
studies are needed to understand the importance of family B1
GPCR oligomerization and its possible role in pathophysiological
conditions,inordertoimprovethedevelopmentof treatmentsfor
these diseases.
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